2022年6月19日 · Tirtha Chakraborty, PhD brings extensive expertise in nucleic acid therapy as well as cell and gene therapy to his role as Chief Scientific Officer. Before joining Vor Bio, Tirtha was Vice President of Cell Therapy Research at Sana Biotechnology.

Tirtha Chakraborty, PhD brings extensive expertise in nucleic acid therapy as well as cell and gene therapy to his role as Chief Scientific Officer. Before joining Vor Bio, Tirtha was Vice President of Cell Therapy Research at Sana Biotechnology.

Tirtha Chakraborty, PhD brings extensive expertise in nucleic acid therapy as well as cell and gene therapy to his role as Chief Scientific Officer. Before joining Vor Bio, Tirtha was Vice President of Cell Therapy Research at Sana Biotechnology.

2019年10月1日 · Tirtha Chakraborty, PhD, a hematological and gene engineering research specialist with experience at Sana Biotechnology and CRISPR Therapeutics, joins as Vice President of Research.

Chakraborty was appointed as Vor Bio’s Chief Scientific Officer after leading efforts to expand the company’s technology platform and advance its science towards the clinic.

TORONTO, July 24, 2023 /PRNewswire/ - Specific Biologics Inc. ("Specific"), a venture-backed, early-stage genome editing company, is pleased to announce it has appointed Tirtha Chakraborty, Ph.D....